A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost doubled – the cure rate for patients with the most common kind of breast cancer. The findings suggest adopting a new treatment paradigm for the disease.
Category: Cancer, Illnesses and conditions, Body & Mind
Tags: Breast cancer, Chemotherapy, Immunotherapy, clinical trials, Peter MacCallum Cancer Centre
